Endologix, Inc. (NASDAQ:ELGX) Director Acquires $19,995.25 in Stock

Endologix, Inc. (NASDAQ:ELGX) Director Thomas F. Zenty III acquired 3,025 shares of the firm’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were bought at an average price of $6.61 per share, with a total value of $19,995.25. Following the completion of the purchase, the director now directly owns 22,053 shares in the company, valued at $145,770.33. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Shares of NASDAQ:ELGX opened at $6.01 on Friday. Endologix, Inc. has a 1 year low of $5.20 and a 1 year high of $67.20. The stock has a market cap of $62.19 million, a P/E ratio of -0.83 and a beta of 0.58. The company has a current ratio of 2.03, a quick ratio of 1.25 and a debt-to-equity ratio of 5.00.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Monday, February 25th. The medical instruments supplier reported ($2.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($21.00) by $18.90. The business had revenue of $34.69 million for the quarter, compared to analyst estimates of $34.00 million. Endologix had a negative return on equity of 138.32% and a negative net margin of 50.94%. Research analysts expect that Endologix, Inc. will post -4.76 EPS for the current fiscal year.

A number of brokerages recently weighed in on ELGX. Zacks Investment Research upgraded Endologix from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Monday, January 28th. Stifel Nicolaus set a $7.00 price objective on Endologix and gave the stock a “hold” rating in a research note on Monday, April 1st. ValuEngine cut Endologix from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Finally, BTIG Research restated a “buy” rating on shares of Endologix in a research note on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $25.63.

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new position in shares of Endologix in the third quarter valued at about $165,000. Jane Street Group LLC acquired a new position in shares of Endologix in the third quarter valued at about $116,000. Assenagon Asset Management S.A. acquired a new position in shares of Endologix in the fourth quarter valued at about $55,000. Paloma Partners Management Co acquired a new position in shares of Endologix in the third quarter valued at about $184,000. Finally, Two Sigma Investments LP increased its holdings in shares of Endologix by 49.0% in the fourth quarter. Two Sigma Investments LP now owns 804,212 shares of the medical instruments supplier’s stock valued at $576,000 after purchasing an additional 264,453 shares during the period.

WARNING: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/27/endologix-inc-elgx-director-thomas-f-zenty-iii-purchases-3025-shares.html.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Featured Story: How is diluted EPS different from basic EPS?

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.